- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Journal of Oncology
Volume 2009 (2009), Article ID 519563, 10 pages
Inhibition of Glutathione and Thioredoxin Metabolism Enhances Sensitivity to Perifosine in Head and Neck Cancer Cells
Free Radical and Radiation Biology Program, Department of Radiation Oncology, Holden Comprehensive Cancer Center, The University of Iowa, Iowa City, IA 52242, USA
Received 2 March 2009; Accepted 17 June 2009
Academic Editor: Paul Harari
Copyright © 2009 Andrean L. Simons et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- D. R. Spitz, J. E. Sim, L. A. Ridnour, S. S. Galoforo, and Y. J. Lee, “Glucose deprivation-induced oxidative stress in human tumor cells. A fundamental defect in metabolism?” Annals of the New York Academy of Sciences, vol. 899, pp. 349–362, 2000.
- N. Aykin-Burns, I. M. Ahmad, Y. Zhu, L. W. Oberley, and D. R. Spitz, “Increased levels of superoxide and mediate the differential susceptibility of cancer cells versus normal cells to glucose deprivation,” Biochemical Journal, vol. 418, no. 1, pp. 29–37, 2009.
- J. S. Carew and P. Huang, “Mitochondrial defects in cancer,” Molecular Cancer, vol. 1, pp. 1–9, 2002.
- H. Pelicano, R.-H. Xu, M. Du, et al., “Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism,” Journal of Cell Biology, vol. 175, no. 6, pp. 913–923, 2006.
- D. P. Brazil and B. A. Hemmings, “Ten years of protein kinase B signalling: a hard Akt to follow,” Trends in Biochemical Sciences, vol. 26, no. 11, pp. 657–664, 2001.
- G. Song, G. Ouyang, and S. Bao, “The activation of Akt/PKB signaling pathway and cell survival,” Journal of Cellular and Molecular Medicine, vol. 9, no. 1, pp. 59–71, 2005.
- M. Sun, G. Wang, J. E. Paciga, et al., “AKT1/PKB kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells,” American Journal of Pathology, vol. 159, no. 2, pp. 431–437, 2001.
- P. Amornphimoltham, V. Sriuranpong, V. Patel, et al., “Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01,” Clinical Cancer Research, vol. 10, no. 12, pp. 4029–4037, 2004.
- A. A. Konstantinov, A. V. Peskin, E. Y. Popova, G. B. Khomutov, and E. K. Ruuge, “Superoxide generation by the respiratory chain of tumor mitochondria,” Biochimica et Biophysica Acta, vol. 894, no. 1, pp. 1–10, 1987.
- T. P. Szatrowski and C. F. Nathan, “Production of large amounts of hydrogen peroxide by human tumor cells,” Cancer Research, vol. 51, no. 3, pp. 794–798, 1991.
- S. Toyokuni, K. Okamoto, J. Yodoi, and H. Hiai, “Persistent oxidative stress in cancer,” FEBS Letters, vol. 358, no. 1, pp. 1–3, 1995.
- M. Crul, H. Rosing, G. J. de Klerk, et al., “Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours,” European Journal of Cancer, vol. 38, no. 12, pp. 1615–1621, 2002.
- L. Van Ummersen, K. Binger, J. Volkman, et al., “A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer,” Clinical Cancer Research, vol. 10, no. 22, pp. 7450–7456, 2004.
- H. H. Bailey, M. R. Mahoney, D. S. Ettinger, et al., “Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma,” Cancer, vol. 107, no. 10, pp. 2462–2467, 2006.
- A. Argiris, E. Cohen, T. Karrison, et al., “A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer,” Cancer Biology and Therapy, vol. 5, no. 7, pp. 766–770, 2006.
- M. Knowling, M. Blackstein, R. Tozer, et al., “A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial,” Investigational New Drugs, vol. 24, no. 5, pp. 435–439, 2006.
- N. B. Leighl, S. Dent, M. Clemons, et al., “A phase 2 study of perifosine in advanced or metastatic breast cancer,” Breast Cancer Research and Treatment, vol. 108, no. 1, pp. 87–92, 2008.
- P. Hilgard, T. Klenner, J. Stekar, G. Nössner, B. Kutscher, and J. Engel, “D-21266, a new heterocyclic alkylphospholipid with antitumour activity,” European Journal of Cancer, vol. 33, no. 3, pp. 442–446, 1997.
- K. Maly, F. Uberall, C. Schubert, et al., “Interference of new alkylphospholipid analogues with mitogenic signal transduction,” Anti-Cancer Drug Design, vol. 10, no. 5, pp. 411–425, 1995.
- D. Berkovic, “Cytotoxic etherphospholipid analogues,” General Pharmacology, vol. 31, no. 4, pp. 511–517, 1998.
- S. B. Kondapaka, S. S. Singh, G. P. Dasmahapatra, E. A. Sausville, and K. K. Roy, “Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation,” Molecular Cancer Therapeutics, vol. 2, no. 11, pp. 1093–1103, 2003.
- M. E. Anderson, Handbook of Methods for Oxygen Radical Research, CRC Press, Boca Raton, Fla, USA, 1985.
- O. W. Griffith, “Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine,” Analytical Biochemistry, vol. 106, no. 1, pp. 207–212, 1980.
- O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall, “Protein measurement with the folin phenol reagent,” Journal of Biological Chemistry, vol. 193, pp. 265–275, 1951.
- D. R. Spitz, R. R. Malcolm, and R. J. Roberts, “Cytotoxicity and metabolism of 4-hydroxy-2-nonenal and 2-nonenal in -resistant cell lines: do aldehydic by-products of lipid peroxidation contribute to oxidative stress?” Biochemical Journal, vol. 267, no. 2, pp. 453–459, 1990.
- A. Holmgren and M. Bjornstedt, “Thioredoxin and thioredoxin reductase,” Methods in Enzymology, vol. 252, pp. 199–208, 1995.
- F. Q. Schafer and G. R. Buettner, “Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple,” Free Radical Biology and Medicine, vol. 30, no. 11, pp. 1191–1212, 2001.
- X. Leleu, J. Gay, A. M. Roccaro, et al., “Update on therapeutic options in Waldenström macroglobulinemia,” European Journal of Haematology, vol. 82, no. 1, pp. 1–12, 2009.
- M. Moral and J. M. Paramio, “Akt pathway as a target for therapeutic intervention in HNSCC,” Histology and Histopathology, vol. 23, no. 10, pp. 1269–1278, 2008.
- V. Patel, T. Lahusen, T. Sy, E. A. Sausville, J. S. Gutkind, and A. M. Senderowicz, “Perifosine, a novel alkylphospholipid, induces p21WAF1 expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest,” Cancer Research, vol. 62, no. 5, pp. 1401–1409, 2002.
- N. R. Leslie, D. Bennett, Y. E. Lindsay, H. Stewart, A. Gray, and C. P. Downes, “Redox regulation of PI 3-kinase signalling via inactivation of PTEN,” EMBO Journal, vol. 22, no. 20, pp. 5501–5510, 2003.
- N. R. Leslie, “The redox regulation of PI 3-kinase-dependent signaling,” Antioxidants and Redox Signaling, vol. 8, no. 9-10, pp. 1765–1774, 2006.
- M. Kaneki, N. Shimizu, D. Yamada, and K. Chang, “Nitrosative stress and pathogenesis of insulin resistance,” Antioxidants and Redox Signaling, vol. 9, no. 3, pp. 319–329, 2007.
- T. Yasukawa, E. Tokunaga, H. Ota, H. Sugita, J. A. J. Martyn, and M. Kaneki, “S-nitrosylation-dependent inactivation of Akt/protein kinase B in insulin resistance,” Journal of Biological Chemistry, vol. 280, no. 9, pp. 7511–7518, 2005.
- D. R. Spitz, M. T. Kinter, and R. J. Roberts, “Contribution of increased glutathione content to mechanisms of oxidative stress resistance in hydrogen peroxide resistant hamster fibroblasts,” Journal of Cellular Physiology, vol. 165, no. 3, pp. 600–609, 1995.
- B. A. Arrick, O. W. Griffith, and A. Cerami, “Inhibition of glutathione synthesis as a chemotherapeutic strategy for trypanosomiasis,” Journal of Experimental Medicine, vol. 153, no. 3, pp. 720–725, 1981.
- K. K. Andringa, M. C. Coleman, N. Aykin-Burns, et al., “Inhibition of glutamate cysteine ligase activity sensitizes human breast cancer cells to the toxicity of 2-deoxy-D-glucose,” Cancer Research, vol. 66, no. 3, pp. 1605–1610, 2006.
- A. L. Simons, I. M. Ahmad, D. M. Mattson, K. J. Dornfeld, and D. R. Spitz, “2-deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells,” Cancer Research, vol. 67, no. 7, pp. 3364–3370, 2007.
- H. H. Bailey, “L-S,R-buthionine sulfoximine: historical development and clinical issues,” Chemico-Biological Interactions, vol. 111-112, pp. 239–254, 1998.
- D. Mustacich and G. Powis, “Thioredoxin reductase,” Biochemical Journal, vol. 346, pp. 1–8, 2007.
- K. Becker, S. Gromer, R. H. Schirmer, and S. Müller, “Thioredoxin reductase as a pathophysiological factor and drug target,” European Journal of Biochemistry, vol. 267, no. 20, pp. 6118–6125, 2000.
- G. Powis, D. L. Kirkpatrick, M. Angulo, and A. Baker, “Thioredoxin redox control of cell growth and death and the effects of inhibitors,” Chemico-Biological Interactions, vol. 111-112, pp. 23–34, 1998.
- D. K. Smart, K. L. Ortiz, D. Mattson, et al., “Thioredoxin reductase as a potential molecular target for anticancer agents that induce oxidative stress,” Cancer Research, vol. 64, no. 18, pp. 6716–6724, 2004.
- P. Nguyen, R. T. Awwad, D. D. K. Smart, D. R. Spitz, and D. Gius, “Thioredoxin reductase as a novel molecular target for cancer therapy,” Cancer Letters, vol. 236, no. 2, pp. 164–174, 2006.
- C. F. Shaw III, “Gold-based therapeutics agents,” Chemical Review, vol. 99, pp. 2589–2600, 1999.
- M. J. McKeage, L. Maharaj, and S. J. Berners-Price, “Mechanisms of cytotoxicity and antitumor activity of gold(I) phosphine complexes: the possible role of mitochondria,” Coordination Chemistry Reviews, vol. 232, no. 1-2, pp. 127–135, 2002.
- M. P. Rigobello, A. Folda, M. C. Baldoin, G. Scutari, and A. Bindoli, “Effect of Auranofin on the mitochondrial generation of hydrogen peroxide. Role of thioredoxin reductase,” Free Radical Research, vol. 39, no. 7, pp. 687–695, 2005.
- J. Ceccarelli, L. Delfino, E. Zappia, et al., “The redox state of the lung cancer microenvironment depends on the levels of thioredoxin expressed by tumor cells and affects tumor progression and response to prooxidants,” International Journal of Cancer, vol. 123, no. 8, pp. 1770–1778, 2008.